Precision BioSciences doses first patient in Phase 1/2 PBGENE-DMD Duchenne gene-editing trial

• Precision BioSciences dosed the first patient in August in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy.
• Program aims to permanently edit the dystrophin gene to enable production of near full-length dystrophin, targeting up to 60% of patients.
• Trial is enrolling ambulatory boys ages 2-7 with mutations between exons 45-55 across multiple U.S. sites.
• Results have not been presented; initial safety data are expected by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260824221319) on August 24, 2026, and is solely responsible for the information contained therein.